Due to the distinct mechanisms of action exhibited by myo-inositol and metformin in enhancing insulin sensitivity and regulating hyperinsulinemia, the combined use results in an additive effect for improving clinical outcomes [9]. This evidence concerns the gene INS and Hyperinsulinemia.